| Display title | Chemistry:Ferric derisomaltose |
| Default sort key | Ferric Derisomaltose |
| Page length (in bytes) | 5,761 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 289334 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Smart bot editor |
| Date of page creation | 02:10, 6 February 2024 |
| Latest editor | imported>Smart bot editor |
| Date of latest edit | 02:10, 6 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Ferric derisomaltose (FDI), sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia (IDA) in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease... |
